Fewer than 15 GCC labs run FLAER flow cytometry, holding confirmed PNH cases below 400 against 2,000-3,000 estimated patients.

Paroxysmal nocturnal hemoglobinuria is a clonal haematopoietic stem cell disorder caused by an acquired somatic PIG-A mutation, producing GPI-anchor-deficient blood cells vulnerable to complement-mediated lysis. Across the GCC, an estimated 2,000 to 3,000 patients carry PNH clones large enough to be clinically significant, but only around 400 are confirmed in NPHC and specialist haematology registries. The gap reflects both near-zero community disease awareness outside haematology and a consanguinity rate of 25% to 50% across Gulf populations, which raises the likelihood that a somatic PIG-A mutation acquires clinical significance against a background of higher underlying immune and clonal stress.

The standard PNH diagnostic panel, FLAER flow cytometry plus CD55/CD59, is available at fewer than 15 laboratories across the six GCC states. Most peripheral hospitals either refer samples internationally or fall back on CD55/CD59-only testing, which carries a 20% to 30% false-negative rate for small-clone PNH. Confirmed diagnosis concentrates at specialist centres such as KFSH&RC, which anchors the region's largest published PNH case series. Median time to diagnosis for symptomatic GCC patients runs two to four years, and disease often surfaces first as Budd-Chiari syndrome or aplastic anaemia; PNH-aplasia overlap accounts for 25% to 30% of GCC PNH cases against roughly 15% globally.

A lab-access gap, not disease rarity, hides most GCC PNH patients.

Five questions this report answers:

Q1 - What is the true size of the undiagnosed GCC PNH population, and where does it concentrate?

Q2 - Which GCC laboratories run FLAER flow cytometry, and what does that mean for time-to-treatment?

Q3 - What does compassionate-access-only status mean for near-term GCC uptake of iptacopan?

Q4 - What diagnostic and access barriers define the addressable GCC PNH market?

Q5 - Why does PNH often first present as Budd-Chiari syndrome or aplastic anaemia in the GCC?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PNH #RareDisease #GCCHealthcare #Haematology #DiseaseLandscape #SFDA

Live report page:  https://axlrx.ai/pnh/gcc/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/